CIRM Funded Clinical Trials

Phase 2 Safety and Efficacy Study of CLBS03 Autologous T-Regulatory Cells in Adolescents with Recent Onset Type 1 Diabetes Mellitus


Disease Area:
Investigator:
Institution:
CIRM Grant:
CLIN2-09730 (Closed)
Award Value:
$8,175,946.00
Trial Sponsor:
Trial Stage:
Phase 2
Trial Status:
Completed
Targeted Enrollment:
113
ClinicalTrials.gov ID:

Details:

Children with type 1 diabetes (T1D) face lifelong struggles with┬ácontrolling their blood sugar levels and, despite careful management, an increased risk of severe complications. Currently, there is no approved therapy that maintains or restores the insulin-producing pancreatic beta cells that are destroyed by this disease.┬áResearchers at Caladrius Biosciences will take cells, called regulatory T cells (Tregs), from the patient’s own immune system, expand the number of those cells in the lab and return them to the patient to reduce the autoimmune attack on the insulin-producing cells in people with type 1┬ádiabetes.

Design:

Prospective, randomized, double-blinded, placebo-controlled, proof-of-concept study.

Goal:

Primary: Safety. Secondary: Efficacy.

Updates:

Enrolling; Fast track and Orphan designations.

News about this clinical trial:

Contact Trial Sponsor

CIRM Clinical Trial Resources


Patient Stories of Hope

CIRM Alpha Stem Cell Clinics

Patient Toolbox


Video on Stem Cell Trials


Other Resources

ISSCR Patient Website

ClinicalTrials.gov